The use of AST/ALT ratio in combination with risk scores such as FIB-4 and NAFLD are appropriate screening tools to determine patients at high risk of liver fibrosis who requires further investigation. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.